Drug Development for Parasite-induced Diarrheal Diseases PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Drug Development for Parasite-induced Diarrheal Diseases PDF full book. Access full book title Drug Development for Parasite-induced Diarrheal Diseases by Anjan Debnath. Download full books in PDF and EPUB format.
Author: Anjan Debnath
Publisher: Frontiers Media SA
ISBN: 2889452484
Category :
Languages : en
Pages : 179
Get Book Here
Book Description
One of the top four contributors to the global burden of disease is diarrheal infections. Intestinal parasites are major causes of morbidity and mortality associated with diarrheal diseases in both the developed and developing world. Amebiasis is responsible for 50 million cases of invasive disease and 70,000 deaths annually in the world. Giardiasis has an estimated worldwide prevalence of 280 million cases annually. In developed countries, Giardia lamblia infects about 2% of adults and 6-8% of children. The prevalence of G. lamblia infection is generally higher in developing countries, ranging from 3% to 90%. Furthermore, giardial infections contribute substantially to the 2.5 million annual deaths from diarrheal disease. In Asia, Africa, and Latin America, about 500,000 new giardiasis cases are reported each year. Cryptosporidium accounts for 20% and 9% of diarrheal episodes in children in developing and developed countries, respectively. Infection with Cryptosporidium can be chronic and especially debilitating in immunosuppressed individuals and malnourished children. A recent study to measure disease burden, based on disability-adjusted life years (DALYs), found that cryptosporidiosis and amebiasis produce about 10.6 million DALYs. This exceeds the DALYs of any helminth infection currently being targeted by the World Health Organization for preventive chemotherapy. Because of its link with poverty, Giardia and Cryptosporidium were included in the WHO Neglected Diseases Initiative in 2004. E. histolytica, G. lamblia, and C. parvum have been listed by the National Institutes of Health (NIH) as category B priority biodefense pathogens due to low infectious dose and potential for dissemination through compromised food and water supplies in the United States. Despite the prevalence of amebiasis, giardiasis, and cryptosporidiosis there are no vaccines or prophylactic drugs. The first-line drugs for invasive amebiasis and giardiasis chemotherapy are nitroimidazoles, with the prototype, metronidazole, being the most common drug used worldwide. Metronidazole has been shown to be both mutagenic in a microbiological system and carcinogenic to rodents, and frequently causes gastrointestinal side effects. In spite of the efficacy of nitroimidazole drugs, treatment failures in giardiasis occur in up to 20% of cases. Clinical resistance of G. lamblia to metronidazole is proven and cross resistance is a concern with all commonly used antigiardial drugs. Nitazoxanide, the only FDA-approved drug for the treatment of cryptosporidiosis, is effective in the treatment of immunocompetent patients and partially effective for immunosuppressed patients. Therefore, it is critical to search for more effective drugs to treat amebiasis, giardiasis, and cryptosporidiosis. This Research Topic for Frontiers in Microbiology will explore the recent progress in drug development for parasitic diarrheal diseases. This includes an understanding of drug resistance mechanisms. We would also welcome submissions on the drug development for other diarrheal parasites. We hope that this research topic will include a comprehensive survey of various attempts by the parasitology research community to create effective drugs for these diseases.
Author: Anjan Debnath
Publisher: Frontiers Media SA
ISBN: 2889452484
Category :
Languages : en
Pages : 179
Get Book Here
Book Description
One of the top four contributors to the global burden of disease is diarrheal infections. Intestinal parasites are major causes of morbidity and mortality associated with diarrheal diseases in both the developed and developing world. Amebiasis is responsible for 50 million cases of invasive disease and 70,000 deaths annually in the world. Giardiasis has an estimated worldwide prevalence of 280 million cases annually. In developed countries, Giardia lamblia infects about 2% of adults and 6-8% of children. The prevalence of G. lamblia infection is generally higher in developing countries, ranging from 3% to 90%. Furthermore, giardial infections contribute substantially to the 2.5 million annual deaths from diarrheal disease. In Asia, Africa, and Latin America, about 500,000 new giardiasis cases are reported each year. Cryptosporidium accounts for 20% and 9% of diarrheal episodes in children in developing and developed countries, respectively. Infection with Cryptosporidium can be chronic and especially debilitating in immunosuppressed individuals and malnourished children. A recent study to measure disease burden, based on disability-adjusted life years (DALYs), found that cryptosporidiosis and amebiasis produce about 10.6 million DALYs. This exceeds the DALYs of any helminth infection currently being targeted by the World Health Organization for preventive chemotherapy. Because of its link with poverty, Giardia and Cryptosporidium were included in the WHO Neglected Diseases Initiative in 2004. E. histolytica, G. lamblia, and C. parvum have been listed by the National Institutes of Health (NIH) as category B priority biodefense pathogens due to low infectious dose and potential for dissemination through compromised food and water supplies in the United States. Despite the prevalence of amebiasis, giardiasis, and cryptosporidiosis there are no vaccines or prophylactic drugs. The first-line drugs for invasive amebiasis and giardiasis chemotherapy are nitroimidazoles, with the prototype, metronidazole, being the most common drug used worldwide. Metronidazole has been shown to be both mutagenic in a microbiological system and carcinogenic to rodents, and frequently causes gastrointestinal side effects. In spite of the efficacy of nitroimidazole drugs, treatment failures in giardiasis occur in up to 20% of cases. Clinical resistance of G. lamblia to metronidazole is proven and cross resistance is a concern with all commonly used antigiardial drugs. Nitazoxanide, the only FDA-approved drug for the treatment of cryptosporidiosis, is effective in the treatment of immunocompetent patients and partially effective for immunosuppressed patients. Therefore, it is critical to search for more effective drugs to treat amebiasis, giardiasis, and cryptosporidiosis. This Research Topic for Frontiers in Microbiology will explore the recent progress in drug development for parasitic diarrheal diseases. This includes an understanding of drug resistance mechanisms. We would also welcome submissions on the drug development for other diarrheal parasites. We hope that this research topic will include a comprehensive survey of various attempts by the parasitology research community to create effective drugs for these diseases.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 9780309045278
Category : Medical
Languages : en
Pages : 312
Get Book Here
Book Description
Malaria is making a dramatic comeback in the world. The disease is the foremost health challenge in Africa south of the Sahara, and people traveling to malarious areas are at increased risk of malaria-related sickness and death. This book examines the prospects for bringing malaria under control, with specific recommendations for U.S. policy, directions for research and program funding, and appropriate roles for federal and international agencies and the medical and public health communities. The volume reports on the current status of malaria research, prevention, and control efforts worldwide. The authors present study results and commentary on the: Nature, clinical manifestations, diagnosis, and epidemiology of malaria. Biology of the malaria parasite and its vector. Prospects for developing malaria vaccines and improved treatments. Economic, social, and behavioral factors in malaria control.
Author: Anjan Debnath
Publisher: Frontiers Media SA
ISBN: 2889630064
Category :
Languages : en
Pages : 415
Get Book Here
Book Description
Amebiasis, a parasitic disease transmitted by the unicellular protozoan parasite Entamoeba histolytica, is the cause of at least 100,000 deaths each year. The disease is mostly prevalent in developing countries and is one of the three common causes of death from parasitic diseases. The parasite has two stages in its life cycle in the host: the infective cyst and the invasive trophozoite. In the large intestine, the parasite feeds on bacteria and on cellular debris. No vaccine against amebiasis currently exists. Although metronidazole is the drug of choice for treating amebiasis, adverse effects in patients and potential resistance to metronidazole in other protozoa exist. About nine out of 10 people who are infected with E. histolytica are asymptomatic and in those individuals who develop symptoms, bloody diarrhea (amebic colitis) and liver abscess are the most common symptoms. One possible explanation for this observation is the difference in the gut microbiota between individuals that may significantly influence the host’s immune response in amebiasis and E. histolytica's virulence. Amebiasis is characterized by acute inflammation of the intestine with release of pro-inflammatory cytokines, reactive oxygen species and reactive nitrogen species from activated cells of the host's immune system. In recent years, significant advances on the cell biology of Entamoeba infection have been achieved through the development of new genetic tools to manipulate gene expression in the parasite and through the application of Omics tools. In this Research Topic, we welcome high quality original research articles, as well as review, opinion or method articles, on amebiasis including but not limited to the regulation of gene expression, cell biology and signaling, adaptation and resistance to environmental stresses, metabolism, pathogenesis and immunity, pathogenesis and microbiome, drug discovery and drug resistance.
Author: Tomoyoshi Nozaki
Publisher: Springer
ISBN: 4431552006
Category : Medical
Languages : en
Pages : 567
Get Book Here
Book Description
This book documents and presents new developments in the study of amebiasis, one of the neglected tropical diseases. Nearly 50 million people worldwide are infected with the pathogen Entamoeba histolytica, causing large-scale morbidity and mortality particularly in developing countries. This book will help clinicians for better diagnosis and management of the disease, researchers for initiating research projects on some of the poorly understood aspects of the disease and the pathogen, and students for updating their knowledge. The subjects covered range from genomics and molecular and cell biology to drug resistance and new drug development, highlighting major advances in recent years in our understanding due to rapid progress in genomic and other biomedical technologies, such as visualization of molecular processes. Most of the chapters provide recent information based on latest publications. A few chapters describe some of the critical methodological issues that will be helpful for students and researchers interested in getting into the field. The contributing authors include almost all the active researchers and clinicians from around the world. This book will be a useful primary material and a valuable source of information for anyone interested in understanding amebiasis, its diagnosis, and treatment. It will also be useful to those who are interested in learning about the biology of early branching eukaryotes and protist pathogens.
Author: Jane Meschan Foy
Publisher:
ISBN: 9781581109665
Category : Children
Languages : en
Pages : 0
Get Book Here
Book Description
The definitive manual of pediatric medicine - completely updated with 75 new chapters and e-book access.
Author: Karen C. Carroll
Publisher: John Wiley & Sons
ISBN: 1683674812
Category : Medical
Languages : en
Pages : 6886
Get Book Here
Book Description
Revised by a collaborative, international, interdisciplinary team of editors and authors, this edition of the Manual of Clinical Microbiology includes the latest applications of genomics and proteomics and is filled with current findings regarding infectious agents, leading-edge diagnostic methods, laboratory practices, and safety guidelines. This edition also features four new chapters: Diagnostic Stewardship in Clinical Microbiology; Salmonella; Escherichia and Shigella; and Morganellaceae, Erwiniaceae, Hafniaceae, and Selected Enterobacterales. This seminal reference of microbiology continues to set the standard for state-of-the-science laboratory practice as the most authoritative reference in the field of microbiology. If you are looking for online access to the latest from this reference or site access for your lab, please visit www.wiley.com/learn/clinmicronow.
Author: H. Schönfeld
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318032050
Category : Medical
Languages : en
Pages : 303
Get Book Here
Book Description
Author: William C. Campbell
Publisher: Springer Science & Business Media
ISBN: 1461236266
Category : Medical
Languages : en
Pages : 380
Get Book Here
Book Description
Ivermectin and abamectin, members of the avermectin family of compounds, were introduced to the market in the 1980's as a veterinary antiparasitic drug and agricultural pesticide, respectively. Their acceptance and commercial success have been remarkable; both are highly effective and in worldwide use. The efficacy of ivermectin in river blindness has expanded the interest in its use in human medicine. In response to the intense scientific and industrial interest in ivermectin and abamectin and the likelihood that they will be forerunners of an expanding family of drugs, this comprehensive monograph satisfies the need for a review and synthesis of current knowledge about the use of these substances in crop protection as well as in cattle, sheep, swine, horses, dogs, cats, birds, fish, reptiles, and in man. This overview presents chemical, biochemical, and microbiological data, as well as pharmacological, safety, and environmental aspects and covers practical use of the compounds as antiparasitic and pesticide agents, as well as the available safety data that have emerged from the clinical experience with human applications.
Author: C. Graham Clark
Publisher:
ISBN: 9781912530861
Category :
Languages : en
Pages :
Get Book Here
Book Description
In this book internationally acclaimed researchers critically review the most important aspects of research on anaerobic parasitic protozoa, providing the first coherent picture of their genomics and molecular biology since the publication of the genomes. Chapters are written from a molecular and genomic perspective and contain speculative models upon which future research efforts can be based. Topics include: the genomes of Entamoeba histolytica, Trichomonas vaginalis, Giardia and other diplomonads; the cytoskeletons of Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis; genomic.
Author: Gabriela Hrckova
Publisher: Springer Science & Business Media
ISBN: 3709113253
Category : Medical
Languages : en
Pages : 135
Get Book Here
Book Description
The natural world with a large number of terrestrial and marine plants and lower organisms is a great source of bioactive compounds historically used as remedies in various diseases. Within the last decade, such compounds became more attractive targets for pharmacologists and the pharmaceutical industry in drug development projects. This volume presents the pharmacological potential of chemically defined natural compounds obtained from plants, fungi, algae and cyanobacteria with antiparasitic activity, that have been tested against various endo-parasitic protozoan and helminth species. Additionally, the advantages of combined therapy using antiparasitic drugs and natural compounds with selected specific activity are reviewed and explained in the context of host pathology and immunosuppression induced by the parasites. The conclusions of this new book give suggestions for further non-empirical drug development and discuss perspectives of alternative approaches to therapy of parasitic diseases.
